Sonoma Pharmaceuticals, headquartered in Boulder, Colorado, develops hypochlorous acid products for various healthcare applications and went public on January 26, 2007. Their product lineup includes Lumacyn, Regenacyn, and MicrocynAH for skin and wound care.
SNOA has been in the news recently: Williams-Sonoma, Inc. reported a 4.2% increase in revenue to $1.73 billion for fiscal Q1 2025, but its shares fell by 4.48% despite beating earnings and revenue forecasts. Analysts reaffirmed their coverage of the company, with one analyst slightly lowering the price forecast following the mixed results.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
